BAY
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Bayrock Resources Limited
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in BAY
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in BAY
N/A
BAY investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in BAY also invest in...
Want more shares? Try these...
An app that turns an ordinary mobile phone into a device for conducting objective neurobehavioral tests could make it easier and more cost-effective to diagnose neurological disorders. The company is headquartered in Sydney, New South Wales. The company went IPO on 2024-04-04. The Company’s tests include eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response, which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The BlinkLab Device (BlinkLab Dx) consists of BlinkLab App, a mobile application for patients, caregivers and/or parents, effectively a front-end tool that helps collect test subjects’ information and responses to the BlinkLab Tests in real time (BlinkLab App), and BlinkLab Portal, which includes a fully built secure database and content management system (CMS) as well as experimenter’s portal that allows for full customization of the neurometric tests as well as data analysis, annotation and visualization tools (the BlinkLab Portal).
📊 Share price
$0.45 AUD
🩺 HEALTH CARE
